Our Vision

We strive to be a leading enterprise in the global pharmaceutical and healthcare markets.

Our Mission

Better health for families worldwide.

Contents

02 [illegible]

04 [illegible]

05 [illegible]

43 [illegible]

50 [illegible]

51 [illegible]

52 [illegible]

54 [illegible]

56 [illegible]

58 [illegible]

91 [illegible]

Corporate

Directors

Executive Director

- (吳以芳)
  ( )

Non-executive Directors

- (陳啟宇)
- (姚方)
- (徐曉亮)
- (龔平)
- (潘東輝)
- (張厚林)

Independent Non-executive Directors

- (李玲)
- (湯谷良)
- (王全弟)[1]
- (余梓山)[1]
- (江憲)[2]
- (黃天祐)[2]

Supervisors

- (任倩) ( )
- (曹根興)
- (管一民)

Joint Company Secretaries

- (董曉嫻)
- (甘美霞)

Authorized Representatives

- (吳以芳)
- (甘美霞)

Strategic Committee

- (陳啟宇) ( )
- (吳以芳)
- (姚方)
- (徐曉亮)
- (李玲)

Audit Committee

- (湯谷良) ( )
- (王全弟)[1]
- (龔平)
- (江憲)[2]

Nomination Committee

- (王全弟)[1]( )
- (李玲)
- (潘東輝)
- (江憲)[2]

Remuneration and Appraisal Committee

- (余梓山)[1]( )
- (湯谷良)
- (王全弟)[1]
- (陳啟宇)
- (潘東輝)
- (江憲)[2]
- (黃天祐)[2]

Environmental, Social and Governance Committee

- (余梓山)[1]( )
- (李玲)
- (吳以芳)
- (黃天祐)[2]

Registered Office

10 , 2000 3,

Principal Place of Business in the PRC

12 , 200233,

[1] 11 2021
[2] 11 2021

Corporate

Principal Place of Business in Hong Kong

4,
183

Legal Advisers in Hong Kong

Legal Advisers in the PRC

Auditors

Principal Banks

Company Name

Stock Abbreviation

Share Listing

001

021

A Share Registrar and Transfer Office in the PRC

H Share Registrar and Transfer Office in Hong Kong

4,
183

Company's Website

Financial

	For the six months ended 30 June	
	2021	2020
	RMB million	
Operating results		
	16,878	13,
	8,767	, 4
	1,343	1,2 2
P	**3,304**	2,302
P	**2,482**	1, 1
D	**4,670**	3,
Profitability		
	51.94%	.4 %
	7.96%	.2 %
	16.32%	13. %
Earnings per share ( )		
	0.97	0.
	0.97	0.
Of which: Pharmaceutical manufacturing segment		
	12,179	, 2
	7,072	,1
m	**1,353**	1,11
m	**1,257**	1,11

	30 June 2021	31 D m 2020
	RMB million	
Assets		
	88,422	3, 2
	37,804	3 , 3
	41,383	3 , 02
	10,489	, 2
D	**46.80%**	4 .0 %

FINANCIAL REVIEW

[illegible]

[illegible] 20.[illegible] %.

[illegible] 2,4[illegible]2 m [illegible] 44. %. [illegible] 0 m [illegible] 1 . %. [illegible] &D [illegible] 4 m [illegible] 1 . %. [illegible] &D [illegible] 2 m [illegible] 2 . 3%. [illegible] (1) [illegible] ([illegible]), [illegible] ([illegible]), [illegible] ([illegible]), [illegible] (2) [illegible]

[illegible] 44. [illegible]% [illegible] 2020.

REVENUE

[illegible] 20.[illegible] %. [illegible] 1, [illegible]0 m [illegible] 1,1 [illegible] m [illegible] 30.[illegible]0%.

[illegible] 2,1 m [illegible] 22.3[illegible]%. [illegible] 3 3 m [illegible] 21.24%. [illegible] 2 m [illegible]), [illegible] 12. 4% [illegible]

COST OF SALES

[illegible] 30.4 % [illegible],111 m [illegible] 2,21 m [illegible] 2020.

GROSS PROFIT

[illegible] 13.14% [illegible], [illegible] 4 m [illegible] 2020. [illegible] 2020 [illegible] 1. 4% [illegible] .4 %, [illegible].

Management
Discussion and Analysis

SELLING AND DISTRIBUTION EXPENSES

[illegible] 10.84% [illegible] 4,3[illegible] m [illegible] RMB, 31 m[illegible] 2020.

R&D EXPENSES AND R&D EXPENDITURE

[illegible] &D [illegible] &D [illegible] RMB, 4 m[illegible] 1 . %. [illegible] &D [illegible] RMB, 2 m[illegible] 8 m[illegible] 2 . 3%. [illegible] &D [illegible] RMB23 m[illegible] 1 .31%, [illegible] 14. 1% [illegible] RMB,3[illegible] m[illegible] RMB2 m[illegible] 30. [illegible]%, [illegible] 11.31% [illegible] &D [illegible]

SHARE OF PROFITS OF ASSOCIATES

[illegible] 32.4 % [illegible] RMB2 m[illegible] RMB m[illegible] 2020.

PROFIT FOR THE PERIOD

[illegible] 44.1 % [illegible] RMB, 4 m[illegible] RMB, 10 m[illegible] 2020. [illegible] 2020 [illegible] 1 .32% [illegible] 13. %, [illegible].

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

[illegible] RMB,482 m[illegible] 44. % [illegible] RMB, 1 m[illegible] 2020. [illegible] (1) [illegible] (2) [illegible]

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

30 2021, [illegible] ,213 m [illegible] 23, 43 m [illegible] 31 D m 2020 m [illegible] P [illegible] 30 2021, m [illegible] B . % [illegible] 1. [illegible] m [illegible] 38.34% [illegible] 31 D m [illegible] 2020. D [illegible] P [illegible] m [illegible] m [illegible] 30 2021, [illegible] .2 % [illegible] 0,48 m [illegible] 2 m [illegible] 31 D m 2020.

30 2021, [illegible] m [illegible] 42 m (31 D m 2020 [illegible] 1 m) [illegible] m [illegible] m [illegible]

30 2021, [illegible] m [illegible] ,220 m (31 D m 2020 [illegible] 4, 48 m).

Cash and cash equivalents denominated in:	30 June 2021	31 D m 2020
[illegible]	7,269	,214
[illegible]	164	2,1 4
	2,564	2,30
[illegible]	72	41
[illegible]	420	208
[illegible]	10,489	, 2

Gearing Ratio

30 2021, [illegible] 28. 1%, [illegible] 28.3 % [illegible] 31 D m 2020.

Interest Rate

30 2021, [illegible] 40, 38 m (31 D m 2020 [illegible] 1,03 m).

Management

Maturity Structure of Outstanding Debts

	[illegible]	[illegible]
	30 June 2021	31 D m r 2020
1 [illegible]	**15,992**	14, 40
1 2 [illegible]	**2,847**	,801
2 [illegible]	**4,564**	4
[illegible]	**1,810**	4
[illegible]	**25,213**	23, 43

Available Facilities

[illegible] 30 2021, [illegible] 0,4 m [illegible] 4,3 m [illegible] m [illegible] m [illegible] 30 2021, [illegible] 0,1 m [illegible] 41 m [illegible]

Collateral and Pledged Assets

[illegible] 30 2021, [illegible] m [illegible] (31 D m 2020 [illegible] m), [illegible] m [illegible] (31 D m 2020 [illegible] 2 m), [illegible] m [illegible] 3 m [illegible] m [illegible] (31 D m 2020 [illegible] m) [illegible] m [illegible] (31 D m 2020 [illegible] m).

[illegible] 30 2021, [illegible] m [illegible] m [illegible] (31 D m 2020 [illegible])

D [illegible] 1 [illegible]

Cash Flow

[illegible] 2020.

	January – June 2021	2020
[illegible]	**1,707**	1,4[illegible]1
[illegible]	**(2,450)**	(2,3[illegible])
[illegible]	**770**	[illegible]2
[illegible]	**27**	(1)
[illegible]	**7,325**	[illegible],2[illegible]4
[illegible]	**7,248**	[illegible],1

Capital Commitments and Capital Expenditures

[illegible] 2,041 [illegible]

Management

RISK MANAGEMENT

Foreign Currency Exposure

Interest Rate Exposure

BUSINESS REVIEW

1. Discussion and Analysis on Operations

	Revenue Jan – Jun 2021 Amount	Percentage of revenue (%)	2020	(%)	(%)
By business segment					
[illegible]	**12,179**	**72.16**	[illegible]	1.2	22.3[illegible]
[illegible]	**2,832**	**16.78**	2,[illegible]3	1[illegible].0	.31
[illegible]	**1,843**	**10.92**	1,3	.3	3 . 1
By geographical locations					
[illegible]	**11,680**	**69.20**	[illegible]4	0.[illegible]	1[illegible].0
[illegible]	**5,198**	**30.80**	4,0 1	2 .1	2 . [illegible]

[illegible] 2021, [illegible] 14.2 % [illegible] 2020. [illegible]

Segment Performance Overview

[illegible] 22.3[illegible]%. [illegible] 21.24%. [illegible] 12. 4% [illegible] 1 .31%. [illegible] 14. 1% [illegible] 11.31% [illegible]

Management

D

D P ( ) A (m) m m m m (1) m (m) m m A 24 m (m) (m m) 223.21% 2020, A 32 m A 20 m (2) m m m P m m P m 32.0% - (m P m) (3) m m (m D-1), m

D

[illegible]

[illegible]

[illegible]

D

.m

( )

2021,

1 -1 ( ) 82%,
( ) 4% 2- (m - 2 .1 m)
( ), m ( ) ( )
83%, 8% 3 %, 4 - (m - 1.1 m)
m 2 .8 m 4 44%.
201 , m 4, 00
D, m m -
( ) .2%. D,
m m m m

D m mm
10,000- -m P
D . - m
- m m
m m m m
m - - m m
m m - m m
m m m m

[illegible]

[illegible]

Table 1 — Major pipeline drug projects

Type	Number	Remarks
[illegible]	2	/
[illegible]	30	[illegible] 2.
[illegible]	2	[illegible] 3. [illegible] 1 [illegible]
[illegible]	13	[illegible] 4. [illegible] 1 [illegible]
[illegible]	18	[illegible] 3 [illegible]
[illegible]	103	/
[illegible]	20	/
[illegible]	38	/
[illegible]		/
[illegible]	240	/

[illegible]

[illegible]

Table 2 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1		-1	- m	P	( )
2		-1 01	m		
3		-1 01	m m	P	P ( )
4		-1	m m	P	
		-1	m 1	P	( )
		1001	m	P	P ( )
		- 4	m m	P	
8		-011	m	P	
		-33	m m	P	( )
10		-43		P	P ( )
11		-0	m m		
12		P01001	m m		
13		-20	m	P	
14	m m m		D	P	
1	m	-20	m	P	
1		103	m		P ( )
1		-2		P	

Table 3 — Biopharmaceutical innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1					
2					
3					
4					
8					
10					
11					
12					
13					
14					
1					
1					
1					
18					
1					
20					

1

2

Table 4 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	[illegible]	[illegible]	[illegible]	[illegible]
2		[illegible]	[illegible]	[illegible]
3	[illegible]	[illegible]	[illegible]	[illegible]
4		[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]
8	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
10	[illegible]	[illegible]	[illegible]	[illegible]
11		[illegible]	[illegible]	[illegible]
12		002	[illegible]	[illegible]
13			[illegible]	[illegible]

Table 5 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	[illegible]	[illegible]	[illegible]	[illegible]
2	[illegible]	[illegible]	[illegible]	[illegible]
3	[illegible]	[illegible]	[illegible]	[illegible]
4	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
8	[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]
10		[illegible]	[illegible]	[illegible]
11		[illegible]	[illegible]	[illegible]
12		[illegible]	[illegible]	[illegible]
13	[illegible]	[illegible]	[illegible]	[illegible]
14		[illegible]	[illegible]	[illegible]

[illegible]

Table 6 — Major drugs approved for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications	Remarks
1	[illegible]	[illegible]	[illegible]	[illegible]
2	[illegible]	[illegible]	[illegible]	
3	[illegible]	[illegible]		[illegible]
4	[illegible]	[illegible]		[illegible]

[illegible] 1TobraAccordhe ReoU.S. FS trationj)Note A ottU.S. eher fReporting Period, a

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Packaging specification	Selected price	Selected quantity
1	4+	[illegible]	[illegible]	[illegible]	[illegible]	0.4	2 ,13
2	[illegible]	[illegible]	[illegible]	10[illegible]	[illegible]	2 .[illegible]	1, 00
3	[illegible]	[illegible]	[illegible]	0.2	[illegible]	.3	2,
4	[illegible]	[illegible]	[illegible]	0.1	10	1.4	4
[illegible]	[illegible]	[illegible]	[illegible]	0.2 [illegible]	10	0.	,3[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	0.1	100	.02	4,2 1
[illegible]	[illegible]	[illegible]	[illegible]	40[illegible]	1	1 .4[illegible]	4,
[illegible]	[illegible]	[illegible]	[illegible]	0.1	30	33.	12, 00
[illegible]	[illegible]	[illegible]	[illegible]	2[illegible]	14	10.[illegible]0	2,21
10	[illegible]	[illegible]	[illegible]	0.2	0	.03	,3 2
11	[illegible]	[illegible]	[illegible]	10[illegible]	14	1 .2	44
12	[illegible]	[illegible]	[illegible]	40[illegible]	32	1 .1	, 00
13	[illegible]	[illegible]	[illegible]	10[illegible]	10	1 . 1	
14	[illegible]	[illegible]	[illegible]	0.	30	20.40	,3 .
1	[illegible]	[illegible]	[illegible]	0.2	30	[illegible].00	1
1	[illegible]	[illegible]	[illegible]	20[illegible]	0	[illegible].[illegible]0	2,10[illegible]
1	[illegible]	[illegible]	[illegible]	0.2	100	1 .4	, [illegible]4
1[illegible]	[illegible]	[illegible]	[illegible]	0.2	30	3 . 0	,300
1	[illegible]	[illegible]	[illegible]	[illegible]	14	1 2. 3	3 0

Management

D

Management

D

D P 2,832 m m .31% m 434 m , 14. 0% - m 4 m , 4. 1% - D m 2020. 2021, m m m m 14.2 % m , m 24.3 % m , m 34. 2% m . m m m m

D

D P m rm &D m, P m (m m), m &D P m m m m m m (m d), - (m) P m mm) m rm &D m P D P - 3000 m m rm - 8000 m m m m m m rm ( ) m P (m) ( ).

D-1 m , m D P rm m m m 2021, m m m m m m - m - m m m m m m

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Financing

[illegible] 2021, [illegible] $200 [illegible]).

2. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1) [illegible]

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
[illegible] *(1)*	1 [illegible]	13, [illegible]	20.[illegible]
[illegible] *(2)*	[illegible],111	,21	30.4
[illegible]	4,3	3, 31	10.[illegible]4
[illegible]	1, 0	1,322	13.[illegible]4
&D [illegible] *(3)*	1, 2	1,204	2 . 3
[illegible]	421	42[illegible]	1. 4
[illegible]	1, 0	1,4 1	1 .
[illegible]	2,4 0	2,3	2. [illegible]
[illegible]	0	[illegible]2	[illegible]

1 [illegible]

2 [illegible]

3 [illegible]

(2) &

① &D

&D	1, 2
&D	3 2
&D	1, 4
&D (%)	11. 3
&D m (%)	14. 1
P &D (%)	20.0

② D

D P &D m m m

m 23 m 1 .31%,

14. 1%

m m m

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
[illegible]	1, 0	3[illegible]3	. 4	2 .	20[illegible]	3.4[illegible]
[illegible]	1,41	2[illegible]3	[illegible]0.00	1 . 2	1.[illegible]0	4.2
[illegible]	2,	1,1 1	.2	4 .30	[illegible]	[illegible].21
[illegible]	1	43	3.02	1[illegible].41	10.42	0. 2
[illegible]	1,024	02	41.21	1 .	24.3[illegible]	20.01
[illegible]		423	2 .	2 .	2[illegible].	0. 2

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
[illegible]	11, [illegible]0	,2[illegible]	4. 2	1[illegible].0	2 .22	3. 1
[illegible]	,1 [illegible]	2,[illegible]22	4 . 1	2 . [illegible]	32. 3	2.13

1 [illegible]

2 [illegible] 2020. [illegible] 2021, [illegible] 0. [illegible]

3 [illegible]

4 [illegible]

5 [illegible]

6 [illegible]

7 [illegible]

C. Subsidiaries and Investees

(1)

①

Company name	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible]	[illegible]	1	,1 2	4,20	2, 1	430	3[illegible]
[illegible]	[illegible]	[illegible]	4 2	,4 3	3,044	3,343	34	31[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible],4	,102	1,[illegible]03	1[illegible]	4 1

②

Company name	Nature of business	Major products	Registered capital	Total assets	Net assets	Revenue	Net profit
	[illegible]	[illegible]	10	2, [illegible]2	2,02	14	4
[illegible]	[illegible]	[illegible]	43	, 30	2,[illegible] 1	34	, 3 4
[illegible]	[illegible]	[illegible]	0	3,0[illegible]0	1, 3	00	103
[illegible]	[illegible]	[illegible]	[illegible]	2, 44	2,223	[illegible]11	112

2

3

4

(2)

10%

Company name	Nature of business	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
			100	344,2 4	4, 0	24 ,120	, 4	,033

(3)

①

m 2020,

100%

P m

* (廣東匯信藥業有限公司)

(m)

P

100%

2021,

P (m P)* (安吉健齒醫療科技合夥企業(有限合夥))

P (m P)* (安吉海躍醫療科技合夥企業(有限合夥)),

0%

P

0%

Name of subsidiary	Acquired through	Net assets (as at the end of the Reporting Period)	Net profit (from date of merger/ acquisition up to the end of the Reporting Period)	Date of acquisition/ merger
[illegible]	[illegible]	3 [illegible]	[illegible]	2 [illegible] 2021
[illegible]	[illegible]	31 [illegible]	1 [illegible]	1 [illegible] 2021

[illegible]

② [illegible]

1 [illegible] 2021, [illegible]

2 [illegible] 2021, [illegible]

2 [illegible] 2021, [illegible]

2 [illegible] 2021, [illegible]

[illegible] 2021, [illegible] 100% [illegible]

2 [illegible] 2021, [illegible] 100% [illegible] 31 [illegible] 2020 [illegible]

31 [illegible] 2021, [illegible] % [illegible]

E. Employees and Remuneration Policies

[illegible]

3. Outlook for Operations in the Second Half of 2021

A. Competition and Development Trends of the Industry

[illegible]

[illegible]

[illegible]

2021,

&D

&D

&D

2021

&D

&D

&D

&D

D

2021,

2021,

2021,

4. Potential Risks

A. Risks in relation to industry policies and system reforms



C. Business and operating risks

(1) &

(2)

(3)

D. Management risks

(1)

(2)

E. Foreign exchange risk

F. Force majeure risks

5. Other Events

A. Shareholding Increase Plan of the Controlling Shareholder

2020

B. The Mandate to Issue Inter-bank Market Debt Financing Instruments

2021 m 2021 2 2021, 3.10% 0

2021 m 2021 2 2021, 2. 0% 120

C. The Public Issuance of Corporate Bonds to Qualified Investors

m ( ) 2021 2 2021, 3. 8%.

D. Proposed non-public issuance of A shares

2 D m 2020, 2020 1 2021, m mm (《中國證監會行政許可申請受理單》) (2100),

2021, m m m 4,4 3. 8 m ( ) m 4, 2.3 m ( ) m m (m d)

2 2021, P m ( ) ., (2021 2 01) m 12 ,144, 2 ( ). 12 m m (. . 2 2021).

E. 2021 Restricted Share Incentive Scheme

2021 m 11 2021. m 2021 m

Statutory
D

RESULTS AND DIVIDENDS

[illegible]

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

[illegible]

DIRECTORS

[illegible]

Executive Director

- (吳以芳) ( )

Non-executive Directors

- (陳啟宇)
- (姚方)
- (徐曉亮)
- (龔平)
- (潘東輝)
- (張厚林)

Independent Non-executive Directors

- (李玲)
- (湯谷良)
- (王全弟)
- (余梓山)

[illegible]

Statutory
D

SUPERVISORS

(任倩) (
(曹根興)
(管一民)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

(北京三元食品股份有限公司) (
(上海百聯集團股份有限公司) (

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

1.1%

2 201 , 1 4, 0 103 ,420 . 102 1 4, 0 . m 1% m .

1 2020, m (1) (10) m , m m .

P

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy)[1]	Option share[1]	Exercise period[1]	Outstanding options as at 1 January 2021	Exercise price per share	Granted during the Reporting Period	Exercised during the Reporting Period	Forfeited or lapsed during the Reporting Period[2]	Outstanding options as at 30 June 2021
		20-11-2020	40%	20-11-2020 2 - -202						
m 2 - -201		31-3-2021	30%	31-3-2021 2 - -202	1,4[illegible]0, 00	42	0	4,3 0	2,100	24,0 0
		31-3-2022	30%	31-3-2022 2 - -202						

(1) m .

(2) D P 2,100 m .

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

30 2021, D m P (m 3 2 m 10

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares[1]	Approximate percentage of Shares in relevant class of Shares
			342,000 ( )	0.0 %
			1,8 , 00 ( )	0.04%
			114,0 ( )	0.01%
			4 ,300 ( )	0.02%

(1) ( )

(2) Long positions in the shares, underlying shares and debentures of the Company's associated corporations (within the meaning of Part XV of the SFO)

Name of Directors/ chief executive	Name of associated corporation	Class of Shares	Capacity	Number of Shares[1]	Approximate percentage of Shares in relevant class of Shares
				22, ,000 ( )[2]	0.2 %
	m			1,4 ( )	0.00%
				40,000 ( )[3]	0.01%
				20,0 ,000 ( )[4]	0.24%
	m			2,32 ( )	0.00%
	P			11,2 0,000 ( )[ ]	0.13%
	m			( )	0.00%
P D				11,1 0,000 ( )[ ]	0.13%
				11,1 0,000 ( )[ ]	0.13%

(1) ( )

(2) 31 2021, 1, 20,000 1,000,000 .

(3) 31 2021, 240,000 400,000 .

(4) 31 2021, 1, 20,000 1,000,000 .

( ) 31 2021, P 4 0,000 1,000,000 .

( ) 31 2021, P D 0,000 1,000,000 .

( ) 31 2021, 0,000 1,000,000 .

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

30 2021,

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares[1]	Approximate percentage of Shares in relevant class of Shares
			1, 33, 00( )	12. %
			3,0 ,2 0( )	4 . %
			,000,000( )[2]	1.0 %
			1, 33, 00( )[2]	12. %
			3,0 ,2 0( )[3]	4 . %
			, 33, 00( )[2]	14.0 %
			3,0 ,2 0( )[3]	4 . %
			, 33, 00( )[2]	14.0 %
			3,0 ,2 0( )[3]	4 . %
			, 33, 00( )[2]	14.0 %
			3,0 ,2 0( )[3]	4 . %
			114,0 ( )	0.01%
			2 ,1 ,1 ( )	.2 %
			1,2 2, 00( )	0.23%
			, 1,1 ( )	1.0 %
			, 4, 3 ( )	1.02%
	m		22,04 ,0 0( )	3. %

(1) ( )

(2) 1, 33, 00 ,000,000 2.14% .2 %

(3) 2.14% .2 %

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Statutory
D

MODEL CODE FOR SECURITIES TRANSACTIONS

COMPLIANCE WITH THE CG CODE

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

11 2021 [illegible] D [illegible] mm [illegible] mm [illegible] 11 2021, [illegible] mm [illegible]

Interim Condensed Consolidated

		For the six months ended 30 June	
		2021	2020
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
REVENUE		**16,877,537**	13, ,1
		(8,110,878)	(,21 ,[illegible] 2)
		8,766,659	, 4 ,30
		141,714	1[illegible]0,42
		(4,356,975)	(3, 31,0)
		(1,505,057)	(1,322,23)
		(1,561,885)	(1,204,42)
		(14,804)	(42,)
		1,645,255	03, 22
		(338,367)	(2,13[illegible])
		116,605	,43
	[illegible]	**(420,725)**	(42 ,[illegible])
		(93,817)	(4 , [illegible])
		925,626	[illegible], 4
PROFIT BEFORE TAX		**3,304,229**	2,301, [illegible]
	10	**(550,647)**	(3 2,0[illegible]1)
PROFIT FOR THE PERIOD		**2,753,582**	1, 0 , 0
		2,482,373	1, 14, 10
		271,209	1 4,[illegible]
		2,753,582	1, 0 , 0
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
		RMB0.97 Yuan	[illegible]
		RMB0.97 Yuan	[illegible]

Interim Condensed Consolidated

F he i m h e ded 30 J e 2021

Interim Condensed Consolidated

30 2021

		30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000
NON-CURRENT ASSETS			
P	13	**11,986,909**	12, ,8 3
		2,574,667	2, ,402
		8,622,217	8, ,24
		9,730,364	, , 41
m		**349,077**	3,81, 1
m		**22,447,860**	21,8 0,
m		**6,243**	1,043
		1,459,128	1,4 0,
D		**232,984**	244, 3
		1,807,055	1,083, 24
		59,216,504	8, 44,320
CURRENT ASSETS			
		5,485,618	,1 2,800
	14	**6,028,237**	4,80 ,0
P		**3,462,140**	2, 4,1
		3,267,854	1, 0,0
D m		**472,998**	28,881
		10,489,133	, 1,802
		29,205,980	2 ,084,803
CURRENT LIABILITIES			
	1	**3,745,584**	3,28 ,021
		6,582,248	, , 4
	1	**15,852,411**	14,488, 4
		140,052	1 1,084
		1,447,288	1,020,30
		389,670	32 ,42
		28,157,253	24,8 2,3 3
NET CURRENT ASSETS		**1,048,727**	212,4 0
TOTAL ASSETS LESS CURRENT LIABILITIES		**60,265,231**	8, , 0

Interim Condensed Consolidated

30 J e 2021

		30 June 2021 RMB'000 (Unaudited)	31 D m 2020 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
	1	**8,513,509**	8,4 , 8
		706,945	2 ,2 1
D		**2,935,378**	2,8 2,
D m		**506,250**	4 2,201
		277,854	2 ,4
		285,708	121, 12
		13,225,644	12,2 ,3 4
Net assets		**47,039,587**	4 , 2 ,3
EQUITY			
Equity attributable to owners of the parent			
		2,562,899	2, 2,
		35,241,150	34,3 , 4
		37,804,049	3 , 3 , 4
Non-controlling interests		**9,235,538**	, , 4
Total equity		**47,039,587**	4 , 2 ,3

Interim Condensed Consolidated

30 2021

	Attributable to owners of the parent									
	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
1 2021 ( )	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
P	—	—	—	—	—	—	2,482,373	2,482,373	271,209	2,753,582
	—	—	2,698	—	—	—	—	2,698	1,722	4,420
	—	—	64,833	—	—	—	—	64,833	—	64,833
	—	—	—	—	—	(164,832)	—	(164,832)	(36,880)	(201,712)
	—	—	67,531	—	—	(164,832)	2,482,373	2,385,072	236,051	2,621,123
	—	—	—	—	(460,551)	—	—	(460,551)	(67,129)	(527,680)
	—	—	—	—	—	—	—	—	9,600	9,600
	—	—	—	—	—	—	—	—	169,710	169,710
	—	—	—	—	9,104	—	—	9,104	37,128	46,232
	—	—	—	—	(17,557)	—	—	(17,557)	—	(17,557)
	—	—	—	—	—	—	—	—	35,420	35,420
	—	—	—	—	—	—	—	—	(65,723)	(65,723)
	—	—	—	(2,449)	—	—	2,449	—	(175,821)	(175,821)
	—	—	—	—	—	—	—	—	58,179	58,179
	—	—	—	—	6,469	—	—	6,469	(4,166)	2,303
	—	—	—	—	45,862	—	—	45,862	13,540	59,402
2020 (11)	—	—	—	—	—	—	(1,102,997)	(1,102,997)	—	(1,102,997)
30 2021 ( )	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656*	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* ,241,1 0,000 (31 D m 2020 4,3 , 4 ,000)

F he i m h e ded 30 J e 2021

	A000	A000	A000	A000	A000	A000	A000	A000	A000	A000
1 2020 (d)	2, 2,	11,3 ,1 2*	(3 , 4)*	2, 23, *	,3 *	(420,)*	14, 1 ,3 *	31,31,1	,31 ,14	3 ,14 ,32
P P							1, 14, 10	1, 14, 10	1 4,	1, 0 , 0
			3,1					3,1	( )	3, 1
			,1					,1		,1
						(1 4, 3)		(1 4, 3)	(100, 3)	(2 , 0)
			100, 10			(1 4, 3)	1, 14, 10	1, 0, 4	4,0 3	1, 4, 40
D					1 , 0			1 , 0	(21,2 1)	(3 1, 4)
					(4)			(4)	2	(22)
D					(2,433)			(2,433)		(2,433)
									24,4	24,4
D									(241, 21)	(241, 21)
									1 2, 4	1 2, 4
					,34			,34	(1 ,3)	(13,010)

Interim Condensed Consolidated

[illegible]

		For the six months ended 30 June	
		2021	2020
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
[illegible]		**2,094,337**	1,[illegible]2[illegible]2
[illegible]		**(387,696)**	(4[illegible],32[illegible])
[illegible]		**1,706,641**	1,4[illegible]1,2
CASH FLOWS FROM INVESTING ACTIVITIES			
P[illegible]		**(2,286,070)**	(1,[illegible]04,14[illegible])
[illegible]	1	**(21,391)**	([illegible],400)
P[illegible]		**(100,172)**	(1[illegible]2,431)
P[illegible]		**(191,752)**	(43[illegible],0[illegible])
D[illegible]		**537,242**	1[illegible]1,1
D[illegible]		**80,764**	4[illegible]4,44
D[illegible]	1[illegible]	**237,609**	
D[illegible]		**61,154**	[illegible],1
D[illegible]		**8,009**	1[illegible],1[illegible]
D[illegible]		**—**	1,0[illegible]
P[illegible]		**18,421**	[illegible],43
([illegible])/[illegible]		**(12,392)**	3,[illegible]4
P[illegible]		**—**	0,22[illegible]
[illegible]		**(819,125)**	([illegible]0,13[illegible])
[illegible]		**37,959**	(42,3[illegible]3)
[illegible]		**(2,449,744)**	(2,3[illegible],33)

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES		
[illegible]	**14,330,459**	[illegible]
[illegible]	**(12,723,895)**	[illegible]
[illegible]	**(419,549)**	[illegible]
[illegible]	**(68,914)**	[illegible]
[illegible]	**251,362**	[illegible]
[illegible]	**—**	[illegible]
[illegible]	**(69,024)**	[illegible]
[illegible]	**(530,770)**	[illegible]
[illegible]	**769,669**	[illegible]
[illegible]	**26,566**	[illegible]
[illegible]	**7,324,881**	[illegible]
[illegible]	**(103,270)**	[illegible]
[illegible]	**7,248,177**	[illegible]
Analysis of balances of cash and cash equivalents:		
[illegible]	**10,489,133**	[illegible]
[illegible]	**(3,240,956)**	[illegible]
[illegible]	**7,248,177**	[illegible]

Notes to Interim Condensed Consolidated

30 2021

1. CORPORATE AND GROUP INFORMATION

2. BASIS OF PREPARATION

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

-1 - 30 2021 (

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

(a) [illegible]

( ) [illegible]

[illegible]

[illegible]

4. OPERATING SEGMENT INFORMATION

[illegible]

(a) [illegible] &D [illegible]

( ) [illegible]

( ) [illegible]

(d) [illegible]

( ) [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue							
[illegible]	12,179,257	2,832,211	1,843,434	—	22,635	—	16,877,537
[illegible]	13,233	17,779	20,501	—	12,639	(64,152)	—
[illegible]	12,192,490	2,849,990	1,863,935	—	35,274	(64,152)	16,877,537
Segment results*	1,352,891	434,099	(19,393)	—	9,266	(23,352)	1,753,511
[illegible]	102,012	14,123	15,428	—	7,430	—	138,993
[illegible]	201,990	2,283	87,416	—	262,270	(111,725)	442,234
[illegible]	85,180	16,516	14,508	—	1,698	(14,636)	103,266
[illegible]	(80,436)	(13,698)	(25,545)	—	(5,312)	21,894	(103,097)
[illegible]	(35,582)	(34,764)	(12,181)	—	(258,830)	—	(341,357)
[illegible]	(93,805)	—	—	—	(12)	—	(93,817)
[illegible]	35,707	90,143	(28,178)	896,991	(69,037)	—	925,626
[illegible]							478,870
[illegible]	1,567,957	508,702	32,055	896,991	(52,527)	(127,819)	3,304,229
[illegible]	(311,399)	(54,486)	(47,288)	—	(2)	—	(413,175)
[illegible]							(137,472)
[illegible]	1,256,558	454,216	(15,233)	896,991	(52,529)	(127,819)	2,753,582
Segment assets:	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	(2,668,056)	82,026,072
[illegible]	342,929	—	—	—	6,148	—	349,077
[illegible]	2,273,758	555,078	1,589,874	15,355,639	2,673,511	—	22,447,860
[illegible]							6,396,412
[illegible]							88,422,484
Segment liabilities:	17,422,127	2,202,799	2,555,456	—	710,137	(10,426,621)	12,463,898
[illegible]							28,918,999
[illegible]							41,382,897
Other segment information:							
[illegible]	643,074	123,971	157,392	—	21,010	—	945,447
[illegible]	(1,288)	25,438	7,872	—	190,114	—	222,136
[illegible]**	1,323,129	137,508	477,910	—	102,565	—	2,041,112

* [illegible]

** [illegible]

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Segment revenue							
[illegible]	, 2,0	2, 3[illegible]	1,3 ,01		1 ,1		13, ,1
[illegible]	4[illegible],2 4	4 , 10	4, 00		[illegible],2 0	(10 ,[illegible] 4)	
[illegible]	10,000,3 0	2, [illegible] ,4	1,3 3, 1		23,44	(10 ,[illegible] 4)	13, ,1
Segment results*	1,11 , 13	0 , 4	31,3 3		(4,2[illegible])	(1 ,02)	1, 33,31
[illegible]	13 , 3	10, 1	1 , 10		1 ,		1 , 13
[illegible]	1 , 04	14,210	3,3 3		2 ,233	30	4 0, 0
[illegible]	,12	10,34	1 , 31		1[illegible]	(,2 1)	[illegible]
[illegible]	(1,3 3)	(14,12)	(1 ,40)		(, [illegible])	2 ,1 0	(2,304)
[illegible]	2 , 0	(,433)	(,2)		(22,0 2)		(,1)
[illegible]	(4 , 44)				([illegible]14)		(4 , [illegible])
[illegible]	32, [illegible]1	24,021	(31,134)	24,041	(0, 4)		[illegible], 4
[illegible]							(4,)
[illegible]	1,42[illegible],20[illegible]	4 ,31	14,3	24,041	20[illegible], 00	1,[illegible]3	2,301, [illegible]
[illegible]	(313,433)	(, 2)	(12, [illegible]4)		(23)		(3 2,0[illegible]1)
[illegible]	1,114,	433, 0	1, 13	24,041	20[illegible],3 1	1,[illegible]3	1, 0 , 0
Segment assets:	41,04 ,332	[illegible],2 2,3	,[illegible]12, [illegible]1	13,[illegible] , 0	4,2 1,314	(1, [illegible]3,1)	, [illegible],40
[illegible]	34 ,4 4				, 30		3 ,204
[illegible]	2,24[illegible], [illegible]1	1,102, 0	1, 24,2[illegible]3	13,[illegible] , 0	2,[illegible] ,201		21, 12,444
[illegible]							4, 44,4
[illegible]							[illegible]0,112,[illegible]
Segment liabilities:	1[illegible], 4,1	1, 3 , [illegible]0	2,22 ,[illegible]24		3[illegible] ,141	(,3 0,02[illegible])	13,[illegible]3 ,[illegible]
[illegible]							2 ,4 ,1
[illegible]							40,314,0
Other segment information:							
[illegible]	0,	,1 0	133, 01		1 ,1		[illegible]3 ,2
[illegible]	(32,2 1)	4 , [illegible]	2,3		22,04[illegible]		41,[illegible]4[illegible]
[illegible]**	1,30 ,44	, [illegible]4	3 ,[illegible]		4 , 3		1,[illegible]12,2 0

* [illegible]

** [illegible]

5. REVENUE

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 RMB'000 (Unaudited)
	16,864,028	13, 1,41
	13,509	13, 1
	16,877,537	13, ,1

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2021 (unaudited)

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare service RMB'000	Other business operations RMB'000	Total RMB'000
Types of goods or services					
	11,733,205	2,742,001	37,479	—	14,512,685
	414,422	76,259	1,804,041	11,459	2,306,181
	30,599	13,951	612	—	45,162
	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Geographical markets					
	8,474,661	1,339,179	1,842,132	10,040	11,666,012
	3,703,565	1,493,032	—	1,419	5,198,016
	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Timing of revenue recognition					
	11,763,804	2,755,952	38,091	—	14,557,847
	297,157	13,239	1,804,041	11,459	2,125,896
	117,265	63,020	—	—	180,285
	12,178,226	2,832,211	1,842,132	11,459	16,864,028

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2020 (unaudited)

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Types of goods or services					
[illegible]	, 10,123	2,421,[illegible]1	2 ,[illegible]0		12,0 [illegible],[illegible]11
[illegible]	2[illegible]3, 34	1 [illegible], 01	1,331,14	3, 2	1,[illegible]1 ,20[illegible]
[illegible]	,3[illegible]	1[illegible],014			,3
[illegible]	, 1,242	2, 3[illegible],4	1,3 , 4	3, 2	13, 1,41[illegible]
Geographical markets					
[illegible]	,1 2,1[illegible]	1,32 ,2	1,3 , 4	2,[illegible]04	,[illegible]0,242
[illegible]	2, ,0 3	1,311,201		22	4,0 1,1
[illegible]	, 1,242	2, 3[illegible],4	1,3 , 4	3, 2	13, 1,41[illegible]
Timing of revenue recognition					
[illegible]	, , 0[illegible]	2,43 ,[illegible]	2 ,[illegible]0		12,134,210
[illegible]	21 ,0 1	1 ,0	1,331,14	3, 2	1, 1[illegible],001
[illegible]	, 3	31, 44			,20
[illegible]	, 1,242	2, 3[illegible],4	1,3 , 4	3, 2	13, 1,41[illegible]

6. OTHER INCOME

	For the six months ended 30 June	
	2021	2020
	RMB'000	[illegible]000
	(Unaudited)	[illegible]
[illegible]	8,009	20,3 1
[illegible]	132,660	1 ,3
[illegible]	1,045	1, 1
	141,714	1 0,42

7. OTHER GAINS

	For the six months ended 30 June	
	2021	2020
	RMB'000	[illegible]000
	(Unaudited)	[illegible]
[illegible]	279,501	,20
[illegible]	1,182,759	23,3 4
[illegible]	47,549	41 , 0
[illegible]	78,995	
[illegible]	56,451	,311
	1,645,255	03, 22

8. FINANCE COSTS

	For the six months ended 30 June	
	2021	2020
	RMB'000	[illegible]000
	(Unaudited)	[illegible]
[illegible]	413,098	42 ,
[illegible]	14,841	12,1
[illegible]	(7,214)	(,)
[illegible]	420,725	42 ,

9. PROFIT BEFORE TAX

[illegible]

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
[illegible]	**6,433,620**	4,[illegible]32,[illegible]00
[illegible]	**1,677,258**	1,2[illegible]2,[illegible]2
[illegible]	**3,070,335**	2,4[illegible],2
[illegible]	**180,142**	[illegible],4[illegible]3
[illegible]	**101,061**	[illegible]3,
[illegible]	**39,619**	3[illegible],[illegible]1
	3,391,157	2,[illegible],0[illegible]1
[illegible]	**1,494,528**	1,1[illegible],[illegible]4
[illegible]	**21,673**	12,[illegible]3
[illegible]	**564,429**	4[illegible]0,4
[illegible]	**101,351**	1,0[illegible]
[illegible]	**279,667**	2[illegible]4,24
[illegible]	**16,953**	([illegible]1[illegible])
[illegible]	**15,022**	40,0[illegible]
[illegible]	**(218)**	2,[illegible]
[illegible]	**190,379**	
[illegible]	**(1,182,759)**	(23,3[illegible]4)
[illegible]	**(47,549)**	(41[illegible],0[illegible])
[illegible]	**(41,939)**	([illegible],[illegible]1)
[illegible]	**10,166**	(1,[illegible]21)

10. INCOME TAX

2 % (m 30
2020 2 %) P m
1 200 ,
0% 20%.

1 . % m
%. m
23%.
2 .1 %. m
20. %. m 2 . %.

m m 30 2021 2020

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
	451,937	4 ,32
D	**98,710**	(,24)
	550,647	3 2,0 1

11. DIVIDENDS

D mm m m 30
2021 (m 30 2020).

0.43 ( ) 31 D m 2020
11 2021.

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

[illegible]

[illegible]

[illegible]

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(unaudited)	(Restated)
Earnings		
P[illegible]	**2,482,373**	1,[illegible]14,[illegible]10
P[illegible]	**2,482,373**	1,[illegible]14,[illegible]10

	Number of shares For the six months ended 30 June	
	2021	2020
	(unaudited)	(Restated)
Shares		
[illegible]	**2,562,898,545**	2,[illegible]2,[illegible]8,[illegible]4
[illegible]	**2,562,898,545**	2,[illegible]2,[illegible]8,[illegible]4

[illegible] 30 2021.

13. PROPERTY, PLANT AND EQUIPMENT

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
	12,579,873	10, 20, 0
	1,481,681	1,1 1, 24
	790	14, 3
D	**(46,840)**	(,3 3)
D	**(1,434,727)**	
D P	**(564,429)**	(4 0, 4)
m	**(29,439)**	(4 ,3 3)
30	**11,986,909**	11,313,[illegible]4

m 2020 ,000 (31 D m 2020 ,000),

14. TRADE AND BILLS RECEIVABLES

	30 June 2021	31 D m 2020
	RMB'000	RMB'000
	(Unaudited)	(Audited)
	5,989,288	4, 4,
	38,949	242,400
	6,028,237	4,[illegible]0 ,0

14. TRADE AND BILLS RECEIVABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000 ( )
1	**5,983,688**	4,4 4,
1 2	**144,645**	1 , 30
2 3	**13,640**	42, 0
3	**140,781**	121, 3
P m m	**(293,466)**	(2 0, 2)
	5,989,288	4, 4,

30 2021, 4,300,000 (2020 4,300,000)

15. TRADE AND BILLS PAYABLES

	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000 ( )
	3,208,429	2, 42,0 1
	537,155	34 , 30
	3,745,584	3,2 ,021

-m m.

15. TRADE AND BILLS PAYABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000
1	3,152,144	2,[illegible]1, 1
1, 2	39,361	44, 2
2, 3	12,770	[illegible],
3	4,154	,0 1
	3,208,429	2, 42,0 1

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

		30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000
	(1)		
		1,302,115	1,0 4, 31
		16,335,918	1 ,24 ,[illegible] 3
		17,638,033	1 ,344, 24
mm	(2)	1,500,000	
	(3)	5,227,887	, 20,10
		24,365,920	22, 4, 31
P		(15,852,411)	(14,4[illegible], 4)
-		8,513,509	[illegible],4 , [illegible]

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

[illegible]

	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 ¥000 (d)
[illegible]		
1 [illegible]	15,852,411	14,4[illegible], 4
1 2 [illegible]	2,664,956	, 42, 33
2 [illegible]	4,226,672	2 ,3[illegible]
[illegible]	1,621,881	,3
	24,365,920	22, 4, 31
P [illegible]	(15,852,411)	(14,4[illegible], 4)
[illegible]	8,513,509	[illegible],4 , [illegible]

/

(1) Bank loans

[illegible] m 0.3000% [illegible] .2 00% (31 D m 2020 0.3000% [illegible] .2000%) [illegible] m.

[illegible] 30 2021, [illegible] m [illegible] 13) [illegible] ,2[illegible] ,000 (31 D m 2020 [illegible],42 ,000), [illegible] 31 D m 2020 [illegible] 2[illegible], 04,000).

[illegible] 30 2021, [illegible] m [illegible] ,300,000 (31 D m 2020 [illegible],300,000) [illegible] m [illegible],4 ,000 (31 D m 2020 [illegible],30 ,000).

[illegible] 30 2021, [illegible] m [illegible] 0,0 0,000 (31 D m 2020 [illegible])

[illegible] 30 2021, [illegible] m [illegible] 2, 40,000 (31 D m 2020 [illegible])

[illegible] 30 2021, [illegible] m [illegible] [illegible]3,000 (31 D m 2020 [illegible])

(2) Super Short-term Commercial Paper

[illegible] 2021, [illegible] m [illegible] 00,000,000, [illegible] 2 0% [illegible] m. [illegible] 22 [illegible] m 2021.

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

( )

(3) Corporate bonds

14 201 m ,2 0,000,000, 4. 0% m. 14 2022. 14 2020, 8,0 0,000 14 2022. 3.4 %. 30 2021.

13 2018, m ,300,000,000, 10% m. 13 2023. m 2021), 30 2021.

30 m 2018, m 00,000,000 ,000,000,000, 4.4 % 4. 8% m 30 m 2022. 2 m 2020, 0,000,000 m 2 m 2022. 3.83%. 30 m 2023. m 2021), 30 2021.

2 2021, m , 00,000,000, 3. 8% m. 2 202 .

17. BUSINESS COMBINATION

2 2021, 100% P m ., * (深圳信生藥業有限公司) ( ) m 8,4 0,000. 100%

1 2021, m ., 0% * (上海星苑達醫療科技有限公司) ( ) m 22,400,000. 0%

* m m P m m m m m m .

17. BUSINESS COMBINATION (Continued)

		Fair value recognised on acquisition
		RMB'000
P m	13	0
		34,30
		,34
		,0
		(4, 41)
D		(,4 2)
		3 ,4 0
		(, 00)
		2 , 0
		2 , 0

	RMB'000
	(12, 0)
	,0
	(, 1)
P m 31 D m 2020	(1 , 40)
m	(21,3 1)

17. BUSINESS COMBINATION (Continued)

1 2021	,034, 4
m	(,032)
30 2021	, 1
1 2021	(3 , 00)
30 2021	(3 , 00)
1 2021	,24
30 2021	22,21

,000 ,000 30 2021.

,000 2, 3, 2,000,

18. DISPOSAL OF SUBSIDIARIES

30 2021, 100% (遠東腸衣食品有限公司), 40,000.

30 2021, % (台州市立浙東醫養投資管理有限公司), 31,4 ,000.

30 2021,

18. DISPOSAL OF SUBSIDIARIES (Continued)

[illegible] 100% [illegible] 31 D m 2020 [illegible] ([illegible]). [illegible] 0,000,000 [illegible] (D [illegible] (2021) [illegible] . 100) [illegible] m [illegible] 31 D m 2020, [illegible] m [illegible] ,113,000 [illegible] 88 [illegible] 3,[illegible] ,000. [illegible] m [illegible] 2021, [illegible] mm [illegible] m [illegible] 2021. [illegible]

[illegible]

* [illegible] m [illegible] P [illegible] m [illegible] m [illegible] m [illegible] m [illegible] .

[illegible]

18. DISPOSAL OF SUBSIDIARIES (Continued)

	RMB'000
	11,120
	34 , 3
	(10,0 4)
	23 , 0

19. COMMITMENTS

	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 RMB'000 (d)
	2,334,273	2, 2,44
	834,921	0 , 3
	498,805	342,
	3,193,706	4,003,22
	6,861,705	2 ,10

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
[illegible] *(4 & 6 & 15)*	**1,809,891**	1,3[illegible]32
[illegible] *(1 & 4 & 16)*	**326,501**	1[illegible],33
[illegible] *(1 & 4)*	**7,936**	4,030
[illegible] *(1 & 4)*	**5,139**	
[illegible] *(1 & 4)*	**2,436**	
[illegible] *(1 & 4 & 6)*	**2,039**	3
[illegible] *(2 & 4)*	**2,030**	14
[illegible] *(1 & 4)*	**1,251**	1,
[illegible] *(2 & 4)*	**671**	40
[illegible] *(1 & 4)*	**637**	2,
[illegible] *(3 & 4 & 10 & 16)*	**252**	[illegible],
[illegible] *(4 & [illegible])*	**148**	4,31
[illegible] *(4 & [illegible])*	**40**	[illegible]4,4 1
[illegible] *(1 & 4)*	**26**	13
[illegible] *(4 & 7)*	**19**	1
[illegible] *(1 & 4)*	**6**	[illegible]
[illegible] *(4 & [illegible])*	**6**	1
[illegible] *(4 & [illegible])*	**4**	42
[illegible] *(1 & 4)*	**3**	3
[illegible] *(1 & 4)*	**—**	2, [illegible]
[illegible] *(4 & [illegible])*	**—**	,03
[illegible] *(2 & 4 & 17)*	**—**	1, 12
[illegible] *(1 & 4)*	**—**	1,2 2
	2,159,035	1, 2, [illegible]

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee	For the six months ended 30 June 2021 RMB'000 (Unaudited)	2020 [illegible]000 ([illegible])
[illegible] (3 & 5 & 13 & 16)	5,242	2, 2
D[illegible] P (5 & [illegible])	114	11
S[illegible] P (5 & [illegible])	41	43
	5,397	3,112

Property management services	For the six months ended 30 June 2021 RMB'000 (Unaudited)	2020 [illegible]000 ([illegible])
[illegible] (3 & 5 & 14 & 16)	6,818	, 04

(d) Loans from/to a related parties

[illegible] 2020 [illegible] 31 D[illegible] 2022. [illegible] ,000,000,000. [illegible] ,000,000,000.

Deposits in Fosun Finance	30 June 2021 RMB'000 (Unaudited)	31 D[illegible] 2020 [illegible]000 ([illegible])
[illegible] (3 & 16)	965,024	44 , 0

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

A loan from a related party	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000
(3 & 16)	73,450	,300

. dr , m dr(dr) rdx r ( ) m dr
,814,000 3%.

P m D m 10% m dr
,840,000

( ) dr rdr dr r
,400,000 3.8 %.

m dr rdr dr r
4,2 1,000 m dr m rdr

Loans to related parties	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000
( ) m dr(1)	5,814	8 ,830
dr (2)	188,840	1 ,840
dr r (1)	7,691	
	202,345	1 , 0

(e) Interest income from/interest expense to related parties

Interest income	Six months ended 30 June 2021 RMB'000 (Unaudited)	2020 000
dr (2)	4,678	4, 0
(3 & 16)	4,560	3,3 8
dr r (1)	182	
( ) m dr(1)	112	1 0
	9,532	8,224

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

[illegible] 0.3 % ([illegible] 30 2020 0.3 %), [illegible] 1.[illegible] % ([illegible] 30 2020 1.[illegible] %), [illegible] 1.1 % ([illegible] 30 2020 1.1 %), [illegible] 1. % 1. % ([illegible] 30 2020 1. % 3.[illegible] %).

	Six months ended 30 June	
	2021	2020
	RMB'000	[illegible]000
Interest expense	**(Unaudited)**	[illegible]
[illegible] ([illegible] 3 & 16)	**1,432**	1,0[illegible]

[illegible]

(1) [illegible]

(2) [illegible]

(3) [illegible]

(4) [illegible]

([illegible]) [illegible]

([illegible]) [illegible]

([illegible]) [illegible]

([illegible]) [illegible]

([illegible]) [illegible] 2021, [illegible] 100% [illegible]

(10) [illegible]

(11) [illegible]

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

(12) D

(13) D

(14) D

(1)

(1) 14

(1) D 1 2020,

(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2021	2020
	RMB'000	000
	(Unaudited)	
P	**49,724**	0,0 1
	17,451	1 ,410
P	**526**	243
	67,701	, 04

(g) Guarantees

	Guarantee amount	Start date	End date	Fulfilled or not
	108, 2,000	2021/ /22	2021/12/2	
	43, 0 ,000	2021/ /1	2021/12/2	

30 2021,

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Donations

	Six months ended 30 June	
	2021	2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
[illegible]	**8,708**	1 , [illegible]

[illegible] m [illegible] 30 2021, [illegible] RMB8,0[illegible],000 (m [illegible] 30 2020 RMB , ,000) [illegible]

(i) Outstanding balances with related parties:

( ) [illegible] 30 2021, [illegible] RMB,[illegible]32, 22,000 (31 D m 2020 RMB 3,4 ,000). [illegible]

( ) [illegible] 30 2021, [illegible] RMB,00 , 23,000 (31 D m 2020 RMB , 2 ,000). [illegible]

( ) [illegible] 30 2021, [illegible] RMB , ,000 (31 D m 2020 RMB 2, 14,000) [illegible]

( ) [illegible] 30 2021, [illegible] RMB4,041,000 (31 D m 2020 RMB, 0,000) [illegible]

( ) [illegible] 30 2021, [illegible] RMB ,44 ,000 (31 D m 2020 RMB32, ,000). [illegible]

( ) [illegible] 30 2021, [illegible] RMB3 , 23,000 (31 D m 2020 RMB00, 3[illegible],000) [illegible]

( ) [illegible] 30 2021, [illegible] RMB,43 ,000 (31 D m 2020 RMB,44 ,000) [illegible]

( ) [illegible] 30 2021, [illegible] RMB3 ,000 (31 D m 2020 RMB0, 3,000) [illegible]

20. RELATED PARTY TRANSACTIONS (Continued)

(i) Outstanding balances with related parties: (Continued)

( )

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

	Carrying amounts		Fair values	
	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000 ( )	30 June 2021 RMB'000 (Unaudited)	31 D m 2020 000 ( )
Financial Assets:				
	6,243	1,043	6,243	1,043
D m m	472,998	2 ,1 1	472,998	2 ,1 1
	4,726,982	3,430,	4,726,982	3,430,
	294,076	1 ,40	297,354	1 ,40
	5,500,299	4,24 , 2	5,503,577	4,24 , 2
Financial liabilities:				
	6,674,021	,14 ,4	6,694,426	,1 2,11
( )	5,227,887	, 20,10	5,195,438	, 3,003
	248,335	241, 3	248,335	241, 3
	71,200	3, 03	71,200	3, 03
	12,221,443	14,0 1,2	12,209,399	14,1 0,3

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

[illegible]

[illegible]

[illegible] 30 2021 [illegible]

[illegible]

[illegible] 30 2021

Unobservable inputs for Level 3 assets

[illegible] 3 [illegible]

[illegible] 3.

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities

[illegible] 1,200,000 (31 D m 2020 3, 03,000) D (, D) 2020.

Fair value hierarchy

[illegible]

Assets measured at fair value:

30 2021 ( )

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
[illegible]	3,017,461	206,237	1,503,284	4,726,982
[illegible]	—	6,243	—	6,243
[illegible]	—	472,998	—	472,998
	3,017,461	685,478	1,503,284	5,206,223

31 2020 ( )

	[illegible] (1) RMB'000	(2) RMB'000	(3) RMB'000	RMB'000
[illegible]	1,21 ,4 1	01,3[illegible]	1, 14,02[illegible]	3,430,[illegible]
[illegible]		1,043		1,043
[illegible]		2[illegible]1		2[illegible]1
	1,21 ,4 1	1,331,310	1, 14,02[illegible]	4,0 0, [illegible]

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

m m 3

30 2021

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
1 2021	1,514,028	—
	(159,575)	—
	(9,123)	—
	191,582	—
D	(33,628)	—
30 2021	1,503,284	—

m m 3

30 2020

	[illegible] RMB'000 (Unaudited)	[illegible] RMB'000 (Unaudited)
1 2020	1,[illegible]2 , 24	3,24
	11[illegible], 4	,2[illegible]4
	[illegible],3	
D	(321,)	
	2, [illegible]	
30 2020	1, 4,00	, 30

D [illegible] 4, ,000 [illegible] 2 [illegible] 1 (m [illegible] 30 2020) [illegible] 3 [illegible] (m [illegible] 30 2020).

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

30 2021 ( )

	Fair value measurement using			
	Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
m	—	—	71,200	71,200

31 2020 ( )

	(1) A000	(2) A000	(3) A000	A000
m			3, 03	3, 03

m m m 3 P

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 A000
1	73,503	2,(1,244
	(2,303)	
	—	3 ,02
	—	(20 ,2)
30	71,200	2, 43, 4

D m 1 2 (m 30 2020).

22. CONTINGENT LIABILITIES

[illegible]

23. EVENTS AFTER THE REPORTING PERIOD

Sold back of the "18 Fosun Pharma 01" Corporate Bonds

[illegible]

Placing of new shares of Sisram Medical Ltd

[illegible]

24. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

[illegible]

Definitions

[illegible]	[illegible]
%	[illegible]
[illegible]	[illegible] .00 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] D [illegible])
[illegible]	[illegible] D [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible] 14	[illegible]
[illegible] P	[illegible] P [illegible]
[illegible]	[illegible] * (重慶星榮醫美醫院管理有限公司), [illegible]
[illegible]	[illegible]
[illegible]	[illegible] P [illegible] ([illegible]) [illegible] * (上海復星醫藥(集團)股份有限公司), [illegible] P [illegible]
[illegible]	[illegible]

Definitions

[illegible]	[illegible] mm [illegible] * (中國證券監督管理委員會), [illegible] P [illegible] m [illegible]
D [illegible] (r)	[illegible] (r) [illegible] m [illegible]
D P	D [illegible] P [illegible]
[illegible]	[illegible]
[illegible]	[illegible] ., [illegible]* (遠東腸衣食品有限公司)
[illegible]	[illegible] m [illegible]* (佛山復星禪誠醫院有限公司), [illegible] m [illegible] m [illegible]* (佛山市禪城區中心醫院有限公司), [illegible] m [illegible] P [illegible] D [illegible] D [illegible] (佛山市禪城區人口和衛生藥品監督管理局), [illegible] m [illegible]
[illegible]	[illegible] D m [illegible] ., [illegible]* (佛山禪曦房地產開發有限公司)
[illegible]	[illegible] m [illegible] ., [illegible]* (上海復星醫療系統有限公司), [illegible] m [illegible]
[illegible]	[illegible] ([illegible]) ., [illegible]* (上海復星健康科技(集團)有限公司), [illegible] m [illegible] ([illegible]) ., [illegible]* (上海復星醫療(集團)有限公司), [illegible] m [illegible]
[illegible]	[illegible] ([illegible]) m [illegible] m [illegible]* (上海復星高科技(集團)有限公司), [illegible] - [illegible] m [illegible] . [illegible] 14 .0 (1) [illegible]
[illegible]	[illegible] m [illegible] (復星控股有限公司), [illegible] - [illegible] m [illegible]
[illegible]	[illegible] m [illegible] (復星國際控股有限公司), [illegible] (8 .2 % [illegible] 14. 1% [illegible] P [illegible] m [illegible]
[illegible]	[illegible] m [illegible] (復星國際有限公司), [illegible] m [illegible] , [illegible] (5 [illegible] 00)
[illegible]	[illegible] ., [illegible]* (復星凱特生物科技有限公司), [illegible] m [illegible]
P [illegible]	[illegible] P [illegible] D m [illegible] m [illegible] m [illegible]* (上海復星醫藥產業發展有限公司), [illegible] m [illegible]

	2 201 201
P	
	( )
	( ) .00
	(r)
$	
	m
	P
	( ) ., m
	(直觀復星醫療器械技術(上海)有限公司),
	P m* (錦州奧鴻藥業有限責任公司),
	., * (上海科麟國際貨運代理有限公司), 2 2021

Definitions

[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 10 [illegible]
[illegible]	[illegible] * (中華人民共和國國家藥品監督管理局), [illegible]
[illegible]	[illegible]
&D	[illegible]
[illegible]	[illegible] -m [illegible] 1 [illegible] 2021 [illegible] 30 2021
[illegible]	[illegible] * (重慶醫工院製藥有限責任公司), [illegible] 1 [illegible] 2021
[illegible]	[illegible]
[illegible]	[illegible] ([illegible] 1 [illegible]), [illegible]
[illegible]	[illegible] * (上海博億雅醫療器械有限責任公司), [illegible] 2 [illegible] 2021
[illegible]	[illegible] * (上海復宏漢霖生物技術股份有限公司), [illegible] (S [illegible] 02) [illegible]
[illegible]	[illegible] ([illegible])* (上海礪麟醫療管理合夥企業(有限合夥)), [illegible] 2 [illegible] 2021
[illegible]	[illegible] * (《上海證券交易所股票上市規則》)
[illegible]	[illegible] * (上海證券交易所)
[illegible] (r)"	[illegible] (r) [illegible]
[illegible]	[illegible] .00 [illegible]
[illegible]	[illegible] * (瀋陽天晟達商貿有限公司)

	(深圳信生藥業有限公司), (廣東匯信藥業有限公司),
	(國藥產業投資有限公司),
	(國藥控股股份有限公司),
(r)	
	(宿遷市鐘吾醫院有限責任公司)/ (宿遷市腫瘤醫院),
	(台州市投資有限公司)
	(台州浙東醫養投資管理有限公司)
	(江蘇萬邦雲健康科技有限公司),
	(江蘇萬邦生化醫藥集團有限責任公司),
	(瀋陽萬邦天晟生物科技有限公司),
-P	-P
	(《董事/有關僱員進行證券交易的書面指引》)

Definitions

(武漢濟和醫院有限公司),

(上海星苑達醫療科技有限公司),

(徐州星晨婦兒醫院有限公司),

(重慶藥友製藥有限責任公司),

(上海豫園旅遊商城(集團)股份有限公司),